10-K: Nuwellis, Inc. Reports 10-K Filing: Focus on Aquadex System and Fluid Overload Treatment

Nuwellis, Inc. files its 10-K, highlighting its focus on the Aquadex System for treating fluid overload and its commercial activities in heart failure, critical care, and pediatrics.

Summary

• Nuwellis, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing the Aquadex System for ultrafiltration therapy.
• The Aquadex System is used for temporary or extended use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics.
• The company is focusing its commercial activities in three primary clinical areas where fluid overload is prevalent: heart failure, critical care, and pediatrics.
• The company estimates it has treated more than 30,000 patients across all three customer categories since it reintroduced the Aquadex System to the U.S. market in 2016.
• The company believes the total U.S. heart failure market is approximately $1 billion, the total U.S. critical care failure market is approximately $900 million, and the total U.S. pediatric market for fluid overload is approximately $130 million.
• In February 2025, a re-appraisal of the complete dataset from the AVOID-HF trial, demonstrated that patients treated with adjustable ultrafiltration (AUF) had a 60% reduction in heart failure events (HF) at 30 days (p=0.014) compared to adjustable intravenous diuretics (ALD) and significantly fewer HF hospitalizations at 30 days (p=0.032).
• The Company intends to submit an IDE with the FDA in the third quarter of 2026, with U.S. commercialization of this product expected in the second quarter of 2028.
• As of December 31, 2024, the company had 38 full-time employees.
• The company's largest customer represented 14.4% of its 2024 annual revenue.
• The company has identified a material weakness in connection with its internal control over financial reporting which, if not remediated, could adversely affect its business, reputation and stock price.
• The company believes that it has sufficient capital to fund its operations through May 31, 2025.
• The company incurred a net loss of $11.2 million as of December 31, 2024, and its accumulated deficit was $298.8 million.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the FDA clearance and clinical trial results, the company's financial losses, accumulated deficit, and need for additional capital raise concerns.

Positives

• The Aquadex System is FDA-cleared for patients 20 kg or more with fluid overload unresponsive to diuretics.
• The company estimates it has treated more than 30,000 patients since 2016.
• A re-appraisal of the AVOID-HF trial demonstrated a 60% reduction in heart failure events with adjustable ultrafiltration (AUF) compared to adjustable intravenous diuretics (ALD).
• The company is developing a CRRT device for pediatric patients, with commercialization expected in the second quarter of 2028.

Negatives

• The company has identified a material weakness in connection with its internal control over financial reporting which, if not remediated, could adversely affect its business, reputation and stock price.
• The company believes that it has sufficient capital to fund its operations through May 31, 2025.
• The company incurred a net loss of $11.2 million as of December 31, 2024, and its accumulated deficit was $298.8 million.
• The company's largest customer represented 14.4% of its 2024 annual revenue.

Risks

• The company has limited history of operations and limited experience in sales and marketing.
• The company has incurred operating losses since its inception and anticipates that it will continue to incur operating losses in the near-term.
• The company will need to raise additional capital to fund its operations beyond May 31, 2025.
• The company's near-term prospects are highly dependent on revenues from a single product, the Aquadex System.
• Nasdaq may delist the company's common stock from its exchange.
• The company depends on a limited number of customers.
• The company has limited commercial manufacturing experience.
• The company depends upon third-party suppliers, including single-source suppliers.
• The company competes against many companies, some of which have longer operating histories, more established products and greater resources.
• Product defects, resulting in lawsuits for product liability, could harm the company's business, results of operations and financial condition.
• The company may face significant risks associated with international operations.
• The company may not be able to protect its intellectual property rights effectively.
• Security breaches, loss of data and other disruptions could compromise sensitive information related to the company's business.

Future Outlook

The company intends to focus on the acute needs of fluid overloaded patients in cardiac surgery and other areas of critical care, while continuing to support heart failure patients in the inpatient setting, and the outpatient setting. The Company intends to submit an IDE with the FDA in the third quarter of 2026, with U.S. commercialization of this product expected in the second quarter of 2028.

Management Comments

• Growing revenue is the key metric employees, stockholders and potential investors will use to judge our performance.

Industry Context

The company operates in the medical technology industry, specifically focusing on fluid management. The report highlights the prevalence of fluid overload in various clinical areas, including heart failure, critical care, and pediatrics, and the need for alternative therapies to diuretics.

Comparison to Industry Standards

• The report mentions competitors such as Baxter's Prismaflex and Medtronic's Carpediem system, which are used for continuous renal replacement therapy.
• The report cites several clinical trials and studies that compare the Aquadex System to standard-of-care treatment with intravenous diuretics.
• The report mentions that the Aquadex System has been shown to have no clinically significant impact on electrolyte balance, blood pressure or heart rate.
• The report mentions that the Aquadex System may be prescribed by any physician and administered by a healthcare provider, both of whom have received training in extracorporeal therapies.

Management Changes

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings, volatility in stock price.
• Employees: Potential impact on job security and compensation due to financial challenges.
• Customers: Continued access to Aquadex System for fluid overload treatment.
• Suppliers: Potential impact on payment terms and order volumes due to financial challenges.
• Creditors: Increased risk due to the company's financial losses and need for additional capital.

Next Steps

• The company intends to submit an IDE with the FDA in the third quarter of 2026, with U.S. commercialization of this product expected in the second quarter of 2028.
• The company plans to continue to assess its internal controls and procedures and take further action as necessary or appropriate to address the material weaknesses.

Key Dates